SCIENTIFIC PROGRAMME
Preliminary Programme
Thursday, March 4, 2027
08.30 Registration Opens
09.30 - 09.40 Welcome Addresses
Welcome Address by the conference president Michael von Bergwelt, Munich, Germany
09.40 – 11.10 Plenary Session 1: Tumor immunology and immunometabolism
09.40 – 10.10
01.01. Immune Surveillance of Metastasis
Stefanie Dougan, Cambridge, MA, United States
10.10 – 10.40
01.02. How monocytes impact T cell immunity in cancer
Anna Obenauf, Vienna, Austria
10.40 – 11.10
01.03. Immunometabolic gatekeeping
Samra Turajlic, London, United Kingdom
11.10 – 11.40 Coffee Break
11.40 – 13.10 Plenary Session 2: New Targets and New Leads
11.40 – 12.10
02.01. USB39 as a therapeutic target and how it can create missplicing as neoantigens
12.10 – 12.40
02.02. The role of DCs in cancer immunotherapies
Jan Böttcher, Tübingen, Germany
12.40 – 13.10
02.03. Fibroblast-Monocytes Axis in Lymphnodes contributes to Metastasis
Angela Riedel, Würzburg, Germany
13.10 – 13.40 Satellite Symposium – Slot 1
13.40 – 14.40 Lunch & Poster Viewing
14.40 – 15.00 Company Pitches
14.40 – 14.50 | 10 min Company Pitch
14.50 – 15.00 | 10 min Company Pitch
15.00 – 17.00 Plenary Session 3: Antibody drug conjugates
15.00 – 15.30
03.01. Immunological mode of action of ADCs
Oliver Kepp, Paris, France
15.30 – 16.00
03.02. IL1RAP antibody drug conjugates
Poul Sorensen, Vancouver, Canada
16.00 – 16.30
03.03. B7-H3-targeted ADC
16.30 – 16.45 | 03.04. Talk from Submitted Abstracts
16.45 – 17.00 | 03.05. Talk from Submitted Abstracts
17.00 – 17.30 Coffee Break
17.30 – 18.30 Plenary Session 4: Cancer vaccines
17.30 – 18.00
04.01. Peptide-based vaccination approaches
Juliane Walz, Tübingen, Germany
18.00-18.30
04.02. Virus-based vaccination approaches
18.30 – 20.00 Welcome Reception and Poster Viewing (at the venue)
Friday, March 5, 2027
08.30 – 09.30 Plenary Session 5: Local immunotherapies
08.30 – 09.00
05.01. Intratumoral CTLA4 for combination treatments in IO
Lambros Tselikas, Paris, France
09.00 – 09.30
05.02. Intratumoral costimulation and other immunotherapies
Ignacio Melero, Pamplona, Spain
09.30 – 10.30 Plenary Session 6: Bispecific antibodies
09.30 – 10.00
06.01. Innovative bispecific antibody design and application strategies
10.00 – 10.30
06.02. T cell engagers becoming a dominant therapy for cancer and autoimmune diseases
Patrick Bäuerle, Cambridge, MA, United States
10.30 – 11.00 Coffee Break
11.00 – 12.30 Plenary Session 7: Multiple Myeloma
11.00 – 11.30
07.01. The immunological determinants within the TME of Multiple Myeloma
Niels Weinhold, Heidelberg, Germany
11.30 – 12.00
07.02. Role of metabolism on multiple myeloma immunotherapies
Sebastian Theurich, Munich, Germany
12.00 – 12.30
07.03. CAR T cells versus bispecific antibodies in multiple myeloma: better or different?
Herman Einsele, Würzburg, Germany
12.30 – 13.00 Satellite Symposium – Slot 2
13.00 – 14.00 Lunch & Poster Viewing
14.00 – 14.30 Satellite Symposium – Slot 3
14.30 – 15.15 Plenary Session 8: Lifetime Achievement Award
ITOC13 Lifetime Achievement Award presented to Prof. Dr. Miriam Merad, New York, NY, United States
15.15 – 16.30 Plenary Session 9: New players in immunooncology
15.15 – 15.45
09.01. Roles of Y chromosome loss on tumor associated macrophage and immunotherapy
Zihai Li, Columbus, OH, United States
15.45 – 16.15
09.02. Androgen blockade and tumor immunity
16.15 – 16.30 | 09.03. Talk from Submitted Abstracts
16.30 – 17.00 Coffee Break
17.00 – 18.00 Plenary Session 10: Young Researcher Session (from submitted abstracts)
17.00 – 17.15 | 10.01. Talk from Submitted Abstracts
17.15 – 17.30 | 10.02. Talk from Submitted Abstracts
17.30 – 17.45 | 10.03. Talk from Submitted Abstracts
17.45 – 18.00 | 10.04. Talk from Submitted Abstracts
18.00 – 19.00
Poster Viewing with Presenters
19.30 ITOC13 Conference Dinner
Saturday, March 6, 2027
08.30 – 10.30 Plenary Session 11: Next immune activating concepts
08.30 – 09.00
11.01. Anti-PD-1 x anti-CTLA-4 bispecifics in cancer immunotherapies
Anna Maria Di Giacomo, Siena, Italy
09.00 – 09.30
11.02. Combining modes of actions: PD1 – VEGF dual targeting
09.30 – 10.00
11.03. Epitope editing for targeted immunotherapies
Lukas Jeker, Basel, Switzerland
10.00 – 10.30
11.04. Guiding immunotherapy developments by clinically relevant biomarkers
Dominik Wolf, Innsbruck, Austria
10.30 – 11.00 Coffee Break
11.00 – 12.00 Plenary Session 12: Cell therapy in hematology
11.00 – 11.30
12.01. The role of T cell phenotype in driving bettered cellular therapies
Luca Gattinoni, Regensburg, Germany
11.30 – 12.00
12.02. Engineering NK cells for cancer treatment
12.00 – 13.45 Plenary Session 13: Cell therapy in oncology
12.00 – 12.30
13.01. Hybrid receptors for controllable cell therapies
12.30 – 13.00
13.02. Engineering controllable cytokine circuits for solid cancer cellular therapies
Suman Mitra, Lille, France
13.00 – 13.15 | 13.03. Talk from Submitted Abstracts
13.15 – 13.30 | 13.04. Talk from Submitted Abstracts
13.30 – 13.45 | 13.05. Talk from Submitted Abstracts
13.45 – 14.15 Plenary Session 14: Best Poster Awards & Closing Remarks
Chair: Sebastian Kobold, Munich, Germany & Michael von Bergwelt, Munich, Germany
14.15 – 15.00 Lunch & Farewell